AU2017366879C1 - Polymorphs of sepiapterin and salts thereof - Google Patents

Polymorphs of sepiapterin and salts thereof Download PDF

Info

Publication number
AU2017366879C1
AU2017366879C1 AU2017366879A AU2017366879A AU2017366879C1 AU 2017366879 C1 AU2017366879 C1 AU 2017366879C1 AU 2017366879 A AU2017366879 A AU 2017366879A AU 2017366879 A AU2017366879 A AU 2017366879A AU 2017366879 C1 AU2017366879 C1 AU 2017366879C1
Authority
AU
Australia
Prior art keywords
free base
crystalline form
sepiapterin
sepiapterin free
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
AU2017366879A
Other languages
English (en)
Other versions
AU2017366879A1 (en
AU2017366879B2 (en
Inventor
Daniel E. Levy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics MP Inc
Original Assignee
PTC Therapeutics MP Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PTC Therapeutics MP Inc filed Critical PTC Therapeutics MP Inc
Publication of AU2017366879A1 publication Critical patent/AU2017366879A1/en
Assigned to PTC THERAPEUTICS MP, INC. reassignment PTC THERAPEUTICS MP, INC. Amend patent request/document other than specification (104) Assignors: CENSA PHARMACEUTICALS INC.
Application granted granted Critical
Publication of AU2017366879B2 publication Critical patent/AU2017366879B2/en
Priority to AU2022203481A priority Critical patent/AU2022203481B2/en
Publication of AU2017366879C1 publication Critical patent/AU2017366879C1/en
Priority to AU2024200344A priority patent/AU2024200344B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2017366879A 2016-11-29 2017-11-28 Polymorphs of sepiapterin and salts thereof Active 2040-07-17 AU2017366879C1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022203481A AU2022203481B2 (en) 2016-11-29 2022-05-23 Polymorphs of sepiapterin and salts thereof
AU2024200344A AU2024200344B2 (en) 2016-11-29 2024-01-18 Polymorphs of sepiapterin and salts thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662427686P 2016-11-29 2016-11-29
US62/427,686 2016-11-29
US201762546390P 2017-08-16 2017-08-16
US62/546,390 2017-08-16
PCT/US2017/063517 WO2018102315A1 (en) 2016-11-29 2017-11-28 Polymoprhs of sepiapterin and salts thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022203481A Division AU2022203481B2 (en) 2016-11-29 2022-05-23 Polymorphs of sepiapterin and salts thereof

Publications (3)

Publication Number Publication Date
AU2017366879A1 AU2017366879A1 (en) 2019-05-30
AU2017366879B2 AU2017366879B2 (en) 2022-02-24
AU2017366879C1 true AU2017366879C1 (en) 2022-08-11

Family

ID=62241930

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2017366879A Active 2040-07-17 AU2017366879C1 (en) 2016-11-29 2017-11-28 Polymorphs of sepiapterin and salts thereof
AU2022203481A Active AU2022203481B2 (en) 2016-11-29 2022-05-23 Polymorphs of sepiapterin and salts thereof
AU2024200344A Active AU2024200344B2 (en) 2016-11-29 2024-01-18 Polymorphs of sepiapterin and salts thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022203481A Active AU2022203481B2 (en) 2016-11-29 2022-05-23 Polymorphs of sepiapterin and salts thereof
AU2024200344A Active AU2024200344B2 (en) 2016-11-29 2024-01-18 Polymorphs of sepiapterin and salts thereof

Country Status (13)

Country Link
US (4) US11072614B2 (https=)
EP (1) EP3548497A4 (https=)
JP (3) JP7148533B2 (https=)
KR (3) KR102561697B1 (https=)
CN (2) CN116903624A (https=)
AU (3) AU2017366879C1 (https=)
BR (1) BR122021026889A8 (https=)
CA (1) CA3043502A1 (https=)
CO (1) CO2019006018A2 (https=)
IL (2) IL266955B2 (https=)
MA (1) MA46973A (https=)
MX (3) MX386520B (https=)
WO (1) WO2018102315A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2562176B1 (en) 2010-04-22 2018-08-15 Nihon University Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same
MA46973A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
JP7811085B2 (ja) * 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
FI3801536T3 (fi) 2018-05-30 2024-08-29 Ptc Therapeutics Mp Inc Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi
EP3801534B1 (en) 2018-05-30 2026-02-18 PTC Therapeutics MP, Inc. Treatment of phenylketonuria with sepiapterin
AU2019277372B2 (en) 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
IL290321B1 (en) 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment
IL291565B1 (en) * 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity
EP4093405A1 (en) 2020-01-24 2022-11-30 PTC Therapeutics MP, Inc. Methods for treating parkinson's disease with sepiapterin
WO2022173823A1 (en) 2021-02-09 2022-08-18 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin
IL305037A (en) 2021-02-09 2023-10-01 Ptc Therapeutics Mp Inc Methods of treating glioblastomas with spiafatrin
PE20241579A1 (es) 2021-09-29 2024-08-01 Ptc Therapeutics Inc Composicion farmaceutica de sepiapterina
WO2024249602A2 (en) * 2023-05-30 2024-12-05 The Board Of Trustees Of The Leland Stanford Junior University Restless leg syndrome (rls) and periodic leg movements (plms) during sleep: biomarker and drug target
CN117205164B (zh) * 2023-09-30 2024-07-26 山东新时代药业有限公司 一种盐酸沙丙蝶呤片剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181254B2 (en) * 2012-05-07 2015-11-10 Shiratori Pharmaceutical Co., Ltd. Method for producing sepiapterin and tetrahydrolactoylpterin

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
EP0722731B1 (en) 1994-08-05 2002-06-05 Suntory Limited Remedy for spinocerebellar degeneration
JP2002515965A (ja) 1995-08-18 2002-05-28 ダブリュー． ランドリ，ドナルド 抗体触媒反応の調節による有機化合物の検出
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
JP2007509909A (ja) 2003-10-31 2007-04-19 アルタナ　ファルマ　アクチエンゲゼルシャフト 呼吸器疾患の治療のためのｂｈ４の使用
JP5184783B2 (ja) 2003-11-17 2013-04-17 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法
PL1708690T3 (pl) 2003-11-17 2017-01-31 Biomarin Pharmaceutical Inc. Leczenie fenyloketonurii za pomocą BH4
EP1687308B1 (en) 2003-11-17 2019-06-12 Merck & Cie Process for preparating (6R)-L-erythrotetrahydrobiopterin hydrochloride crystalline form B from other crystalline forms
KR20070084270A (ko) 2004-11-17 2007-08-24 바이오마린 파머수티컬 인크. 안정한 정제 제형물
JP2008523090A (ja) * 2004-12-08 2008-07-03 バイオマリン ファーマシューティカル インコーポレイテッド 新生児肺高血圧症の治療のための方法および組成物
BRPI0609421B1 (pt) 2005-04-28 2021-06-01 Shiratori Pharmaceutical Co., Ltd. Processos para produção de um composto 1,1-bis-alquil sulfonila, para produção de um composto aldeído, e para produção de um derivado de hidrazona
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
LT2545939T (lt) * 2007-04-11 2021-03-10 Biomarin Pharmaceutical Inc. Tetrahidrobiopterinas, skirtas gydyti ligas, susijusias supadidėjusiu fenilalanino kiekiu
EA017064B1 (ru) 2008-03-10 2012-09-28 Такеда Фармасьютикал Компани Лимитед Кристаллическое производное бензимидазола
WO2010017570A2 (de) 2008-08-12 2010-02-18 Orpha Swiss Gmbh Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
CA2771432A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
EP2562176B1 (en) 2010-04-22 2018-08-15 Nihon University Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same
US9884909B2 (en) * 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
CN103458900A (zh) 2011-03-01 2013-12-18 鲁必康研究私人有限公司 四氢生物蝶呤的稳定组合物
US9216178B2 (en) * 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
EP3468534A4 (en) 2016-06-13 2020-02-05 Meharry Medical College MODULATION OF THE NITROGEN OXIDE SYNTHASE SIGNAL PATH FOR ORAL HEALTH
WO2018019931A1 (en) 2016-07-29 2018-02-01 Dipharma S.A. Pharmaceutical composition kit comprising sapropterin dihydrochloride
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
MA46973A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
TWI765936B (zh) 2016-11-29 2022-06-01 美商東京威力科創Ｆｓｉ股份有限公司 用以對處理腔室中之微電子基板進行處理的平移與旋轉夾頭
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
AU2019277372B2 (en) 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
EP3801534B1 (en) 2018-05-30 2026-02-18 PTC Therapeutics MP, Inc. Treatment of phenylketonuria with sepiapterin
FI3801536T3 (fi) 2018-05-30 2024-08-29 Ptc Therapeutics Mp Inc Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi
IL290321B1 (en) 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment
IL291565B1 (en) 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181254B2 (en) * 2012-05-07 2015-11-10 Shiratori Pharmaceutical Co., Ltd. Method for producing sepiapterin and tetrahydrolactoylpterin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Pfleiderer, W., "Pteridine, LXVIII. Überführung von Biopterin in Sepiapterin und absolute Konfiguration des Sepiapterins." Chemische Berichte, 1979, 112(7), pp: 2750-2755 *
Schircks, B., et al. "Herstellung von (6R,S)5,6,7,8Tetrahydrolbiopterin, 7,8Dihydrolbiopterin, lSepiapterin, Deoxysepiapterin, (6R,S)5,6Dihydrodeoxysepiapterin und 2′Deoxybiopterin." Helv. Chim. Acta, 1978, 61(7), 2731-38 *

Also Published As

Publication number Publication date
JP7148533B2 (ja) 2022-10-05
KR20250051124A (ko) 2025-04-16
BR112019010222A8 (pt) 2022-11-22
US12269829B2 (en) 2025-04-08
KR102789662B1 (ko) 2025-04-03
CO2019006018A2 (es) 2019-06-19
MX2021011676A (es) 2021-10-22
US20240043426A1 (en) 2024-02-08
MA46973A (fr) 2019-10-09
JP2019535836A (ja) 2019-12-12
CN116903624A (zh) 2023-10-20
BR122021026889A2 (https=) 2019-08-27
IL266955A (en) 2019-07-31
WO2018102315A8 (en) 2018-09-07
KR20190086686A (ko) 2019-07-23
JP2024123011A (ja) 2024-09-10
IL301470A (en) 2023-05-01
US11773097B2 (en) 2023-10-03
AU2022203481B2 (en) 2023-10-19
EP3548497A4 (en) 2020-09-02
CA3043502A1 (en) 2018-06-07
CN110248948A (zh) 2019-09-17
AU2022203481A1 (en) 2022-06-16
JP2023002532A (ja) 2023-01-10
AU2024200344A1 (en) 2024-02-08
US11072614B2 (en) 2021-07-27
BR122021026889A8 (pt) 2022-11-22
US20210300930A1 (en) 2021-09-30
AU2024200344B2 (en) 2025-11-06
KR102561697B1 (ko) 2023-07-28
BR112019010222A2 (pt) 2019-08-27
CN110248948B (zh) 2023-07-28
NZ753504A (en) 2025-10-31
EP3548497A1 (en) 2019-10-09
WO2018102315A1 (en) 2018-06-07
IL266955B1 (en) 2023-05-01
US20190308975A1 (en) 2019-10-10
MX2019006206A (es) 2019-08-14
AU2017366879A1 (en) 2019-05-30
MX386520B (es) 2025-03-19
US20250230164A1 (en) 2025-07-17
MX2021011683A (es) 2021-10-22
KR20230117467A (ko) 2023-08-08
AU2017366879B2 (en) 2022-02-24
IL266955B2 (en) 2023-09-01

Similar Documents

Publication Publication Date Title
AU2022203481B2 (en) Polymorphs of sepiapterin and salts thereof
US12325706B2 (en) Polymorphic form of sepiapterin
JP7850663B2 (ja) スピロ環含有キナゾリン化合物
US20210269443A1 (en) Pharmaceutically acceptable salts of sepiapterin
NZ794827A (en) Polymorphs of sepiapterin and salts thereof
BR122025000511A2 (pt) Forma cristalina de base livre de sepiapterina, composição farmacêutica que a compreende, uso da mesma e método de preparação de uma formulação líquida
BR122025000503A2 (pt) Forma cristalina de base livre de sepiapterina, composição farmacêutica que a compreende, uso da mesma e método de preparação de uma formulação líquida
BR112019010222B1 (pt) Formas d e f cristalinas de base livre de sepiapterina, suas composições, usos e método de preparação de uma formulação líquida compreendendo as mesmas
RU2851633C1 (ru) Соединения хиназолина, содержащие спиро-кольцо
WO2025228973A1 (en) Cocrystals of n-{cis-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: PTC THERAPEUTICS MP, INC.

Free format text: FORMER NAME(S): CENSA PHARMACEUTICALS INC.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 MAY 2022

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 04 MAY 2022

FGA Letters patent sealed or granted (standard patent)
NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: SEPHIENCE SEPIAPTERIN

Filing date: 20250717

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: SEPHIENCE SEPIAPTERIN

Filing date: 20250717

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: SEPHIENCE SEPIAPTERIN

Filing date: 20250717

Extension date: 20400717